Stock Events

Stock Events

Regeneron Pharmaceuticals 

$819.09
878
+$13.42+1.67%Thursday 20:00
+$3.91+0.48%Thursday 23:52After hours

Statistics

Day High
825.52
Day Low
800
52W High
859.34
52W Low
572.75
Volume
852,286
Avg. Volume
738,731
Mkt Cap
84.33B
P/E Ratio
16.24
Dividend Yield
0.46%
Dividend
3.76

Upcoming

Dividends

0.46%Dividend Yield
Aug 2026
$0.94
Jun 2026
$0.94
Mar 2026
$0.94
Dec 2025
$0.88
Sep 2025
$0.88
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
5.11%

Earnings

Oct 30Expected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
8.22
10.88
13.54
16.2
Expected EPS
16.198107
Actual EPS
N/A

Financials

31.41%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
14.34BRevenue
4.5BNet Income

Analyst Ratings

$812.21Average Price Target
The highest estimate is ⁦1,030.00⁩.
From 19 ratings within the last 6 months. This is not an investment recommendation.
Buy
74%
Hold
26%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow REGN. It's not an investment recommendation.
Microsoft
250
MSFT
NVIDIA
249
NVDA
Amazon
221
AMZN
Apple
204
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap217.9B
Amgen competes directly with Regeneron in the biotechnology sector, focusing on innovative therapeutics in areas like oncology and cardiovascular disease.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is a competitor in the biopharmaceutical field, particularly in antiviral drugs, which may overlap with Regeneron's infectious disease treatments.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie operates in similar therapeutic areas as Regeneron, including immunology and oncology, making it a direct competitor.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb competes in the biopharmaceutical space, focusing on cancer, HIV/AIDS, and cardiovascular diseases, areas that intersect with Regeneron's interests.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a global pharmaceutical company with a broad product portfolio that includes immunology and oncology drugs, competing with Regeneron's offerings.
Merck
MRK
Mkt Cap356.01B
Merck is known for its strong presence in the pharmaceutical industry, including areas like cancer treatment and infectious diseases, making it a competitor to Regeneron.
Novartis
NVS
Mkt Cap268B
Novartis competes with Regeneron in multiple areas, including ophthalmology and immunology, with a strong focus on research and development.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its biotech division, competes in the oncology and immunology sectors, directly challenging Regeneron's market.
Sanofi
SNY
Mkt Cap95.65B
Sanofi collaborates with Regeneron on some projects but also competes in areas like immunology and rare diseases, making the relationship complex.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca is involved in biopharmaceuticals across several therapeutic areas, including respiratory, cardiovascular, and oncology, competing with Regeneron.

About

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Show More
CEO
Leonard S. Schleifer
Employees
15410
Country
United States
ISIN
US75886F1075
WKN
000881535

Listings

STU
DE
RGO.STU
MX
MX
REGN.MX
VI
AT
REGN.VI
MI
IT
1REGN.MI

0 Comments

Share your thoughts

FAQs

What is Regeneron Pharmaceuticals stock price today?▼
The current price of REGN is $819.09 USD — it has increased by +1.67% in the past 24 hours. Watch Regeneron Pharmaceuticals stock price performance more closely on the chart.
What is Regeneron Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Regeneron Pharmaceuticals stocks are traded under the ticker REGN.
Is Regeneron Pharmaceuticals stock price growing?▼
REGN stock has risen by +3.59% compared to the previous week, the month change is a +2.15% rise, over the last year Regeneron Pharmaceuticals has showed a +42.28% increase.
What is Regeneron Pharmaceuticals market cap?▼
Today Regeneron Pharmaceuticals has the market capitalization of 84.33B
When is the next Regeneron Pharmaceuticals earnings date?▼
Regeneron Pharmaceuticals is going to release the next earnings report on October 30, 2026.
What were Regeneron Pharmaceuticals earnings last quarter?▼
REGN earnings for the last quarter are 14.29 USD per share, whereas the estimation was 10.16 USD resulting in a +40.69% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regeneron Pharmaceuticals revenue for the last year?▼
Regeneron Pharmaceuticals revenue for the last year amounts to 14.34B USD.
What is Regeneron Pharmaceuticals net income for the last year?▼
REGN net income for the last year is 4.5B USD.
Does Regeneron Pharmaceuticals pay dividends?▼
Yes, REGN dividends are paid quarterly. The last dividend per share was 0.94 . As of today, Dividend Yield (FWD)% is 0.46%.
How many employees does Regeneron Pharmaceuticals have?▼
As of October 23, 2026, the company has 15,410 employees.
In which sector is Regeneron Pharmaceuticals located?▼
Regeneron Pharmaceuticals operates in the Health & Wellness sector.
When did Regeneron Pharmaceuticals complete a stock split?▼
Regeneron Pharmaceuticals has not had any recent stock splits.
Where is Regeneron Pharmaceuticals headquartered?▼
Regeneron Pharmaceuticals is headquartered in TARRYTOWN, United States.